Royalty Pharma PLC reports results for the quarter ended in December - Earnings Summary

Royalty Pharma

15/02/2024 16:35

* Royalty Pharma PLC  RPRX.OQ  reported quarterly adjusted
earnings of $1.15​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of $1.56.  The mean expectation of six analysts for the
quarter was for earnings of $1.01 per share. Wall Street
expected results to range from 92 cents to $1.11 per share.
    * Revenue rose 5.3% to $596.00 million from a year ago;
analysts
expected $691.65 million. 
    * Royalty Pharma PLC's reported EPS for the quarter was 83
cents​.
    * The company reported quarterly net income of $494 million.
    * Royalty Pharma PLC shares had risen by 3.6% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 6.1%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Royalty
Pharma
PLC is $45.00 

This summary was machine generated from LSEG data February 15 at
04:34 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      1.01           1.15           Beat
 Sep. 30 2023      0.76           0.79           Beat
 Jun. 30 2023      0.81           0.84           Beat
 Mar. 31 2023      1.27           1.60           Beat